Genomics
PrivateA platform-not-a-P&L bet — the NanoCas ultracompact/extrahepatic editor is a genuinely differentiated, single-AAV asset the liver-only field can't match, but MB-111 is still pre-IND, the last primary valuation is a stale 2021 $1B mark, and 100% of near-term value sits in three partners' hands; WATCHING for the IND clearance + a fresh priced round that proves the platform survived the 2023-2025 biotech winter.
Research
The verdict
A platform-not-a-P&L bet — the NanoCas ultracompact/extrahepatic editor is a genuinely differentiated, single-AAV asset the liver-only field can't match, but MB-111 is still pre-IND, the last primary valuation is a stale 2021 $1B mark, and 100% of near-term value sits in three partners' hands; WATCHING for the IND clearance + a fresh priced round that proves the platform survived the 2023-2025 biotech winter.
Business model (plain terms). Mammoth is a pre-revenue (no product sales) gene-editing platform company. It makes money three ways, none of them from selling a drug yet:
What it actually is. Despite the "genomics" coverage bucket, Mammoth is not a sequencing/genomics-tools company (it is not a Illumina/PacBio/genomics-instruments name). It is a clinical-stage in vivo gene-editing therapeutics platform — closest public comparables are Intellia, Beam, Prime, Verve (now Lilly), CRISPR Therapeutics, Editas, Metagenomi, Tessera. The +clinical overlay is the correct frame: it has a pipeline, not a P&L.
Key products / assets.
Main customers / counterparties. Mammoth's "customers" are its pharma partners (Vertex, Bayer, Regeneron) and — eventually — payers/patients for MB-111. It also signed a 2026 MoU with Abu Dhabi Department of Health / M42 to bring MB-111 into the emirate's clinical-research ecosystem.
Suppliers. Delivery-vehicle and manufacturing dependencies: AAV capsids (Regeneron supplies its own viral-vector expertise in that partnership) and LNP (lipid nanoparticle) formulation for MB-111; CDMO manufacturing for GMP material (undisclosed). See Lens 2.
Competitors. In vivo editing peers (Intellia, Beam, Verve/Lilly, Prime, CRISPR Tx, Editas, Metagenomi, Tessera) for the platform; specifically for the APOC3/triglyceride indication, the read-across rivals are the liver-lipid editors (Verve's PCSK9/ANGPTL3 base-editing programs, now Lilly-owned; CRISPR/Intellia lipid programs) and the RNA/antisense incumbents already on-market or late-stage for apoC-III (Ionis/Akcea's Waylivra/volanesorsen; Arrowhead's plozasiran/ARO-APOC3).
Contract structure / payment terms. Partnership deals are the classic biobucks structure: small upfront + equity, large back-loaded milestones contingent on R&D/regulatory/commercial success, plus royalties. Concentration is extreme — see Lens 4. No recurring/take-or-pay revenue exists.
Map: discovery inputs → Mammoth's editor platform → delivery vehicle → target tissue → patient, with named stakeholders.
Chokepoints & single-source dependencies:
Names or it didn't happen: UC Berkeley (IP), Regeneron (AAV/antibody), Merck (legacy dx manufacturing), Vertex/Bayer (partner-directed programs), Arbutus/Acuitas-class LNP incumbents (FTO overhang), Ionis/Arrowhead (indication-level competitors on APOC3).
The moat, stated sharply: Mammoth is the only in vivo editing company whose enzyme is small enough to reach tissues the rest of the field can't. Nearly every clinical in vivo CRISPR program today (Intellia, Verve, CRISPR Tx) edits the liver, because LNP delivery to hepatocytes is solved and Cas9 is too big for a single AAV. Mammoth's ultracompact editors (NanoCas ~1/3 Cas9 size) fit a single AAV with payload to spare, which is the enabling key to muscle and CNS — a genuinely under-contested frontier.
Moat components:
Bargaining power — who needs whom? Weak-to-mixed today. Mammoth needs the pharma partners' capital and delivery/regulatory muscle more than they need Mammoth (each partner has other editing shots — Vertex has Casgevy + Orna; Regeneron has internal editing). Partners de-risk Mammoth but also own the near-term value (Lens 4). Against generic/commodity Cas9 licensors Mammoth has power (it owns the small-enzyme niche); against big pharma it is a supplier.
Durability check. The moat is real but unproven in the clinic — it is a preclinical/mechanistic moat. Its durability depends on (i) NanoCas extrahepatic editing translating from NHP to human, and (ii) the IP estate surviving the notoriously murky CRISPR patent landscape. If liver editing is where the first $ are and the extrahepatic promise slips, the differentiation thins.
Mammoth has no reported revenue segments (private, pre-revenue; segments.csv empty). The meaningful "segmentation" is by value source / program ownership — and it exposes the single most important structural fact about this company: near-term economic value is overwhelmingly partner-controlled.
| "Segment" (value source) | What it is | Ownership | Near-term $ exposure | Source |
|---|---|---|---|---|
| Partnered programs | Vertex (2 diseases), Bayer (up to 5 liver drugs), Regeneron (multi-target, extrahepatic) | Partner-led; Mammoth = tech + milestones + royalty | ~100% of near-term cash (upfronts + equity + milestones) | |
| Wholly-owned pipeline | MB-111 (APOC3), NanoCas DMD (preclinical) | Mammoth (full value if it works) | High long-term optionality, ~$0 today | |
| Diagnostics (legacy) | DETECTR / DETECTR BOOST | Mammoth | De-emphasized 2023; residual |
Geography: operations concentrated in Brisbane, CA (US). One international footprint: the Abu Dhabi / M42 MoU (2026) to run MB-111 trials in the UAE.
Trend & cause. The mix has moved decisively over 2021→2026 from diagnostics-plus-therapeutics to therapeutics-only, and from partner-dependent to (attempting) partner-plus-owned-pipeline with the MB-111 nomination (Apr 2025). Direction of travel is right (owning more of the value), but the P&L reality is unchanged: revenue today is milestone-lumpy partnership income, not product sales.
No earnings exist. The tape here is the funding history — round-by-round, with the conflict between sources reconciled.
| Round | Date | Amount | Lead / notable investors | Post-money val | Source |
|---|---|---|---|---|---|
| Seed | 2018 (Apr) | ~$23M (reported as Series A) | Mayfield, NFX, 8VC | n/a | |
| Series A | 2018 | $23M | Mayfield (lead), NFX, 8VC | n/a | |
| Series B | 2020-01 | $45M | Decheng Capital (lead), Mayfield, NFX, Verily, Brook Byers, Plum Alley, aMoon | n/a | |
| Series C | late 2020 | $45M | Redmile, Foresite (lead), + Amazon (Alexa Fund) | n/a | |
| Series D | 2021-09 | $150M (announced with the $45M Series C as "$195M across two rounds") | Redmile (lead), Foresite, Senator, Sixth Street, Greenspring, Mayfield, Decheng, NFX, Plum Alley | ~$1B (unicorn) | |
| Regeneron equity | 2024-04 | $95M equity investment (part of the $100M+ deal) | Regeneron (strategic) | n/a — undisclosed |
⚠ Provenance conflict — surfaced explicitly. Some databases (salestools.io) report a "$195M Series D in Aug 2024 at $1B." This is almost certainly a mis-dated aggregation artifact. The credible primary record (TechCrunch, Forbes, GenomeWeb, Fierce Biotech, MedCity — all 2021-09-09) is unambiguous: the $195M was a Sept-2021 event = a $150M Series D + a $45M Series C reported together, and that is what minted the ~$1B unicorn valuation. There is no evidence of a fresh priced primary round in 2024 beyond the Regeneron $95M strategic equity tied to the collaboration. Treat the last true venture valuation as 2021, ~$1B — now >4 years stale.
Total raised. Reported ~$271M (Tracxn/Crunchbase, equity across ~7 rounds) up to ~$375M (some trackers, including partner equity / non-dilutive). Use ~$271M equity + ≥$176M disclosed partnership upfronts/equity (Vertex $41M + Bayer $40M + Regeneron $95M) as the honest two-line framing.
Burn / runway signals. Two rounds of layoffs signal cash discipline under pressure: 35 cut (March 2023, diagnostics wind-down) and 24 cut (May 2025, ~13% of staff, "strategic alignment"). Headcount ~164 employees (May 2026). Management claims a "uniquely strong financial position" (2025) — plausible given the partner upfronts, but unaudited and unverifiable.
Secondary-market mark: $9.12/share as of 2026-05-26 per Nasdaq Private Market. Directionally useful as a liquidity signal; not a fresh primary round and not a clean valuation.
No earnings calls. The signal is the founder/CEO narrative arc across interviews, conference presentations and press releases.
Tone shift: from expansive platform hype (2021) → disciplined survival + focus (2023-25) → clinical-milestone-driven confidence (2025-26). What they stopped saying: diagnostics, "democratize disease detection." What they started saying: "extrahepatic," "single AAV," "first development candidate," "line of sight to the clinic." That is a healthy maturation for a platform company, but it is still a promise-heavy, data-light narrative until the IND clears.
Cap table quality (the IPO-proximity tell). The syndicate is strong and includes crossover-adjacent names, which matters:
Secondary marks / markups. NPM secondary price $9.12/share (2026-05); pre-IPO secondary interest is live on EquityZen and NPM. No disclosed mutual-fund markup/markdown was found — the absence of a fresh crossover-led priced round since 2021 is itself the signal (in the risk-off 2023-25 biotech tape, a private platform not raising a new priced round is common and slightly bearish on valuation).
Mechanism / catalyst comps — the right way to value a pre-revenue editor (by mechanism & clinical-stage, NOT by P/E):
| Company | Modality / target | Lead asset stage | Relevant read-through | Source |
|---|---|---|---|---|
| Intellia | Cas9 in vivo, liver (KLKB1, TTR) | Phase 3 positive (lonvo-z/NTLA-2002, HAE); BLA 2026, launch 2027 | In vivo liver editing works & is durable (3-yr data) — validates the category | |
| Verve → Lilly | base editing, liver (PCSK9, ANGPTL3) | acquired by Lilly for up to $1.3B (Jun 2025) | Big pharma will pay ~$1B+ for a liver-lipid editing platform — direct MB-111 read-through | |
| Beam | base editing (liver + ex vivo) | clinical | base-editing peer; valuation compression across 2023-25 | |
| Prime Medicine | prime editing | early clinical; cut staff/pipeline | cautionary — platform breadth ≠ capital efficiency | |
| CRISPR Therapeutics | Cas9 (Casgevy on-market) + in vivo | commercial (ex vivo) + clinical | the one editor with an approved product | |
| Tessera | "Gene Writing" (RNA-based) | preclinical; raised >$300M Series C (2022) | private-peer benchmark for platform-stage capital | |
| Metagenomi | metagenomics-discovered editors | clinical-stage, public | closest structural twin — discovery-engine editor company | |
| Ionis / Arrowhead | ASO / siRNA vs APOC3 (Waylivra; plozasiran) | on-market / late-stage | the incumbent competition for MB-111's exact indication — must beat "chronic injectable" standard of care |
Multiples: n/a (Mammoth is private; no EV/Sales, P/E, or ROE exists, and fabricating one would violate provenance). The Verve/Lilly up-to-$1.3B and Intellia Phase-3 prints are the honest valuation anchors: they show the ceiling (a validated liver-editing platform can fetch ~$1B+ from pharma) and the bar (you need clinical durability data, which Mammoth does not yet have).
No stock exists, so the "what moves the value" analysis maps to funding + product + partnership events that re-rated the company:
Pattern (what the "market" — i.e. investors/partners — actually reacts to): big-pharma partnership signings and hard preclinical data re-rate Mammoth up; layoffs / strategic resets re-rate it down. The single largest future catalyst is binary and clinical: MB-111 IND clearance + first-in-human dosing. Everything else is a stepping-stone to that.
Capital-allocation history. For a pre-revenue name this is about cash stewardship and deal-making, and here management scores reasonably well: they cut the diagnostics business decisively rather than subsidizing a losing line, monetized the platform three times through non-dilutive-ish partner capital, and trimmed headcount twice to preserve runway toward the MB-111 milestone. The counter-read: two layoff rounds in ~2 years can also signal that the 2021 platform vision was over-scaled and is being walked back under duress. ROE/ROIC: n/a — pre-revenue.
Red flags (management): none egregious found. Watch-items: (1) the dx→Rx→"strategic alignment" sequence is two strategic resets in three years — execution has been reactive to the funding climate as much as proactive; (2) founder-scientist-heavy leadership is a strength for discovery but the Bob-Brown addition implicitly concedes a clinical/regulatory-development gap the org is still filling; (3) valuation discipline unknowable (private, unaudited).
Accounting (private caveat). Mammoth files no audited public financials — there is no income statement, balance sheet or cash-flow statement to forensically dissect, and no 10-K to quote. Everything below is unaudited per public sources. The structural forensic risks for a company of this type:
Regulatory findings. Per regulatory/regulatory-findings.md (read 2026-07-06): Mammoth has no CIK → no SEC EDGAR enforcement search is possible (it is private and not an SEC filer). Non-SEC web search ("Mammoth Biosciences" (FTC OR DOJ OR FDA OR consent decree OR settlement OR penalty) enforcement) surfaced no material enforcement actions, consent decrees, fines, or penalties. The only "legal" overhang is the industry-wide CRISPR patent murk ("clear as mud" per patent attorneys) — a landscape risk, not a Mammoth-specific enforcement matter. There is no equivalent of a 10-K Item 3 to quote (private).
Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (N/A, no CIK), web search, and the absence of any public enforcement or litigation record as of 2026-07-06. Financials unaudited per public sources. The genuine forensic risk is going-concern/runway + dilution, not accounting fraud.
IPO-readiness (private overlay). Note: Mammoth has no entry in research/private-watch.json (checked 2026-07-06), so this is graded from web signals rather than the curated overlay.
+private payoff is to update private-watch.json and set the dossier path so privates.ts shows Mammoth dossier-warm. Deferred here — this run is unattended/breadth-mode and under the wave boundaries I am not editing the research JSON state files. Flag for the next interactive pass: add mammoth-biosciences to private-watch.json (stage: late-stage; readiness ~2.5; catalyst: MB-111 IND).rNPV / value-inflection (clinical overlay). A full rNPV needs peak-sales × PoS × discount inputs that aren't cleanly sourceable; the honest version:
. **PoS at pre-IND ≈ 10-15%** (industry base rate for a novel-modality pre-clinical asset) .--watchlist rules, not logging a forecast in the breadth loop (no genuine committed base case for a private pre-IND asset). If forced, the tracked binary would be: "MB-111 dosed in a Phase 1 trial by 2027-12-31," p≈0.55 `` — a coin-flip-plus, reflecting a real program with a specific 2026 guide but the usual pre-IND slippage risk.No forecast.ts create run (unattended breadth mode + private pre-revenue name — no EPS line exists to forecast).
Bull case. Mammoth owns the one thing the entire in vivo editing field is missing: an editor small enough to leave the liver. NanoCas is wholly owned, engineered from a proprietary discovery engine, and has already shown 30% dystrophin editing in primate muscle from a single AAV — a capability Intellia, Verve, CRISPR Tx structurally cannot match with Cas9. That extrahepatic key unlocks the biggest untapped editing markets (muscle: DMD; eventually CNS), and the Verve→Lilly up-to-$1.3B and Intellia Phase-3 prints prove big pharma will pay ~$1B+ for validated in vivo editing platforms. Three top-tier pharma partners (Vertex, Bayer, Regeneron) have already underwritten the tech with ≥$176M upfront/equity + billions in milestones, MB-111 gives Mammoth a wholly-owned clinical shot on goal in 2026, and the founder bench (Doudna + a proven dealmaker CEO) is best-in-class. If MB-111 clears IND and NanoCas muscle data translates to humans, this is an acquisition target for exactly the Verve premium.
Bear case (2-3 permanent-impairment risks).
Pre-mortem (18 months out, thesis broke — what happened?). MB-111's IND slipped or the Phase 1 showed weak/short-lived APOC3 knockdown vs. the injectable standard of care; NanoCas muscle data failed to replicate the NHP editing in humans; a partner (most damagingly Regeneron) walked or de-prioritized; and Mammoth was forced into a steep down-round or a fire-sale acqui-hire — the platform survived as IP inside a bigger company, but equity holders from the 2021 unicorn round were badly diluted.
Are multiples too high? n/a — private, no multiple. But the 2021 ~$1B valuation is stale and probably above where a 2026 priced round clears, given the sector reset and the pre-IND status.
Contrarian view (what the market refuses to see). Both bulls and bears anchor on MB-111 (a liver/APOC3 program in a crowded space) — but that is a strategic feint. The real, mispriced option is NanoCas as the extrahepatic-editing arms dealer: if single-AAV muscle editing works, Mammoth doesn't need MB-111 to win — it becomes the enabling delivery-editor licensed across the entire muscle/CNS gene-editing industry, a platform toll-road, not a one-drug biotech. The crowd is grading the drug; the value is in the enzyme.
Dismantling the bull case:
Not a stock anymore — a closed M&A. Lilly bought the whole company for $10.50/share cash (closed Jul 2025); the only live "position" is the $3.00 CVR, which pays only if VERVE-102 reaches a US Phase 3 dosing — market priced ~21% odds, a coin-flip dressed as a lottery ticket.
A rare profitable, debt-free genomic-dx compounder (FY25 16% rev growth, $126M FCF) — but the stock has doubled into a 6.5x-sales / ~30x-FCF valuation just as Natera's FDA-approved Signatera CDx occupies the exact MIBC beachhead TrueMRD is launching into. Quality business, priced for flawless MRD execution it has not yet proven. WATCHING; would buy a reimbursement/launch-driven pullback under ~$40.
A founder-led rare-disease engine with real ($673M) revenue and a pioneer at the helm — but it just lost its biggest pipeline bet (setrusumab) and is burning ~$466M/yr against ~$534M cash, so the entire equity now rides on two H2-2026 FDA approvals (UX111 Sep 19, DTX401 Aug 23) closing the gap to a promised 2027 profit. Binary, not compounding.